Beam Therapeutics (BEAM) Cash from Investing Activities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Cash from Investing Activities for 7 consecutive years, with $108.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 14.15% to $108.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$121.4 million through Dec 2025, down 165.64% year-over-year, with the annual reading at -$121.4 million for FY2025, 165.64% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was $108.4 million at Beam Therapeutics, up from $65.7 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $126.3 million in Q4 2024, with the low at -$537.3 million in Q1 2022.
  • Average Cash from Investing Activities over 5 years is -$31.0 million, with a median of -$5.7 million recorded in 2022.
  • The sharpest move saw Cash from Investing Activities plummeted 3186.85% in 2023, then soared 341.43% in 2024.
  • Over 5 years, Cash from Investing Activities stood at -$77.5 million in 2021, then skyrocketed by 246.38% to $113.4 million in 2022, then dropped by 13.52% to $98.1 million in 2023, then rose by 28.73% to $126.3 million in 2024, then decreased by 14.15% to $108.4 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at $108.4 million, $65.7 million, and -$170.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.